Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent

No definition available.

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent
Namespace Prefix:	mrna_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Maximum Amount

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
Namespace Prefix:	mrna_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones
Namespace Prefix:	mrna_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Research And Development Arrangement, Contract To Perform For Others, Number Of Options

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions
Namespace Prefix:	mrna_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee
Namespace Prefix:	mrna_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod
Namespace Prefix:	mrna_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent
Namespace Prefix:	mrna_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent
Namespace Prefix:	mrna_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Termination Period

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
Namespace Prefix:	mrna_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_VEGFAProductAZD8601Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)	1 Months Ended			12 Months Ended
	Jun. 30, 2018	Jan. 31, 2016	Mar. 31, 2013 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2016 USD ($)	Jun. 30, 2019 option	Mar. 31, 2014 USD ($) option milestone
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase to the transaction price				$ (7,100,000)
Additions				4,009,960,000
Combined 2018 AZ Agreements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase to the transaction price				5,000,000.0
2013 AZ Agreements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of options to develop candidates \| option								40
Estimated arrangement consideration								$ 180,000,000.0
Number of milestones \| milestone								3
Option exercise fee			$ 10,000,000.0
Termination period			90 days
Additions			$ 240,000,000.0			$ 10,000,000.0
2013 AZ Agreements \| VEGF-A product (AZD8601)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Additions					$ 30,000,000.0
2013 AZ Agreements \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Earn-out payments			12.00%
2013 AZ Agreements \| Development Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration								$ 100,000,000.0
2013 AZ Agreements \| Regulatory Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration								100,000,000.0
2013 AZ Agreements \| Commercial Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration								$ 200,000,000.0
VEGF Exercise 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase to the transaction price				400,000
2016 AZ Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Termination period		90 days
Suspension period		12 months
2016 AZ Agreement \| Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Tiered royalties		10.00%
2016 AZ Agreement \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Tiered royalties at default rate		20.00%
Tiered royalties		30.00%
2018 A&R Agreements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of options to develop candidates \| option							40
Termination period	90 days
Estimated reimbursement for clinical supply \| VEGF Exercise 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase to the transaction price				$ 2,400,000